Abstract
Growth hormone (GH) deficiency (GHD) in children is defined as impaired production of GH by the pituitary gland that results in growth failure. This disease might be congenital or acquired, and occurs in isolation or in the setting of multiple pituitary hormone deficiency. Isolated GHD has an estimated prevalence of 1 patient per 4000–10,000 live births and can be due to multiple causes, some of which are yet to be determined. Establishing the correct diagnosis remains key in children with short stature, as initiating treatment with recombinant human GH can help them attain their genetically determined adult height. During the past two decades, our understanding of the benefits of continuing GH therapy throughout the transition period from childhood to adulthood has increased. Improvements in transitional care will help alleviate the consequent physical and psychological problems that can arise from adult GHD, although the consequences of a lack of hormone replacement are less severe in adults than in children. In this Review, we discuss the differential diagnosis in children with GHD, including details of clinical presentation, neuroimaging and genetic testing. Furthermore, we highlight advances and issues in the management of GHD, including details of transitional care.
Key points
-
Growth hormone (GH) affects growth, body composition, metabolic profile, bone mineral density and quality of life; a secretory defect leads to impaired growth and function, known as GH deficiency (GHD).
-
GHD can occur in isolation (isolated GHD, IGHD) or in conjunction with other pituitary hormone deficits (multiple pituitary hormone deficiency, MPHD); GHD might be congenital or acquired.
-
GHD is familial in 3–30% of affected patients: in IGHD, the most commonly mutated genes are GH1 or GHRHR, whereas MPHD can be caused by mutations in several pituitary-specific transcription factors.
-
Congenital hypothalamic–pituitary abnormalities confirmed via imaging, such as anterior pituitary hypoplasia, pituitary stalk anomalies and ectopic posterior pituitary, are common in both children with moderate to severe IGHD and those with MPHD.
-
Recombinant human GH (rhGH), 0.16–0.24 mg/kg per week, is used to treat children with GHD; rhGH is best when initiated upon diagnosis and adjusted by serum concentrations of IGF1, height velocity and bone age.
-
Transitional care is the shift from paediatric care to adult treatment that provides full-body maturation, metabolic control and improved quality of life for those at risk of persistent GHD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kelberman, D., Rizzoti, K., Lovell-Badge, R., Robinson, I. C. & Dattani, M. T. Genetic regulation of pituitary gland development in human and mouse. Endocr. Rev. 30, 790–829 (2009).
Fang, Q. et al. Genetics of combined pituitary hormone deficiency: roadmap into the genome Era. Endocr. Rev. 37, 636–675 (2016).
Schilbach, K. & Bidlingmaier, M. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Arch. Endocrinol. Metab. 63, 618–629 (2019).
Dehkhoda, F., Lee, C. M. M., Medina, J. & Brooks, A. J. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Front. Endocrinol. 9, 35 (2018).
Bach, L. A. 40 Years of IGF1: IGF-binding proteins. J. Mol. Endocrinol. 61, T11–T28 (2018).
Blum, W. F. et al. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr. Connect. 7, R212–R222 (2018).
Støving, R. K., Hangaard, J., Hagen, C. & Flyvbjerg, A. Low levels of the 150-kD insulin-like growth factor binding protein 3 ternary complex in patients with anorexia nervosa: effect of partial weight recovery. Horm. Res. 60, 43–48 (2003).
Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J. Clin. Endocrinol. Metab. 85, 3990–3993 (2000).
Sobrier, M. L. et al. Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. J. Clin. Endocrinol. Metab. 91, 4528–4536 (2006).
Garavelli, L. et al. Solitary median maxillary central incisor syndrome: clinical case with a novel mutation of sonic hedgehog. Am. J. Med. Genet. A 127A, 93–95 (2004).
Secco, A. et al. The glucagon test in the diagnosis of growth hormone deficiency in children with short stature younger than 6 years. J. Clin. Endocrinol. Metab. 94, 4251–4257 (2009). This study shows that children younger than 6 years with GHD can have normal GH peaks after glucagon administration.
Flavelle, S. & Cummings, E. Case 2: An unusual case of delayed puberty. Paediatr. Child. Health 17, 505–507 (2012).
Taylor, M. et al. Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J. Pediatr. 161, 855–863 (2012).
El Kholy, M. et al. Normal growth despite combined pituitary hormone deficiency. Horm. Res. Paediatr. 92, 133–142 (2019).
Binder, G. et al. Diagnosis of severe growth hormone deficiency in the newborn. Clin. Endocrinol. 93, 305–311 (2020). A comprehensive and updated review of the pituitary stalk interruption syndrome for further reading.
Grimberg, A. et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm. Res. Paediatr. 86, 361–397 (2016).
Mamilly, L., Pyle-Eilola, A. L., Chaudhari, M. & Henry, R. K. The utility of a random growth hormone level in determining neonatal growth hormone sufficiency. Clin. Endocrinol. 94, 392–398 (2020).
Kelly, A., Tang, R., Becker, S. & Stanley, C. A. Poor specificity of low growth hormone and cortisol levels during fasting hypoglycemia for the diagnoses of growth hormone deficiency and adrenal insufficiency. Pediatrics 122, e522–e528 (2008).
Cohen, P. et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J. Clin. Endocrinol. Metab. 93, 4210–4217 (2008).
Binder, G. et al. GHD diagnostics in Europe and the US: an audit of national guidelines and practice. Horm. Res. Paediatr. 92, 150–156 (2019).
Juul, A. et al. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm. Res. 58, 233–241 (2002).
Murray, P. G., Dattani, M. T. & Clayton, P. E. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch. Dis. Child. 101, 96–100 (2016).
Rosenfeld, R. G. Is growth hormone deficiency a viable diagnosis? J. Clin. Endocrinol. Metab. 82, 349–351 (1997).
Loche, S. et al. Effect of body mass index on the growth hormone response to clonidine stimulation testing in children with short stature. Clin. Endocrinol. 74, 726–731 (2011).
Meinhardt, U. J. & Ho, K. K. Modulation of growth hormone action by sex steroids. Clin. Endocrinol. 65, 413–422 (2006).
Martin, L. G. et al. Effect of androgen on growth hormone secretion and growth in boys with short stature. Acta Endocrinol. 91, 201–212 (1979).
Galazzi, E. et al. Clinical benefits of sex steroids given as a priming prior to GH provocative test or as a growth-promoting therapy in peripubertal growth delays: results of a retrospective study among ENDO-ERN centres. Clin. Endocrinol. 94, 219–228 (2021).
Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555–559 (2011).
Binder, G., Huller, E., Blumenstock, G. & Schweizer, R. Auxology-based cut-off values for biochemical testing of GH secretion in childhood. Growth Horm. IGF Res. 21, 212–218 (2011).
Guzzetti, C. et al. Cut-off limits of the peak GH response to stimulation tests for the diagnosis of GH deficiency in children and adolescents: study in patients with organic GHD. Eur. J. Endocrinol. 175, 41–47 (2016).
Manolopoulou, J. et al. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant. Clin. Chem. 58, 1446–1456 (2012).
Shen, Y. et al. Diagnostic value of serum IGF-1 and IGFBP-3 in growth hormone deficiency: a systematic review with meta-analysis. Eur. J. Pediatr. 174, 419–427 (2015).
Ibba, A. et al. IGF1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal. Endocr. Connect. 9, 1095–1102 (2020).
Felício, J. S. et al. Diagnosis of idiopathic GHD in children based on response to rhGH treatment: the importance of GH provocative tests and IGF-1. Front. Endocrinol. 10, 638 (2019).
Hadjadj, S. et al. Diagnostic strategy for growth hormone deficiency: relevance of IGF-1 determination as a screening test. Ann. Endocrinol. 68, 449–455 (2007).
Ranke, M. B. et al. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm. Res. 55, 115–124 (2001).
Mavromati, M. et al. Classification of patients with GH disorders may vary according to the IGF-I assay. J. Clin. Endocrinol. Metab. 102, 2844–2852 (2017).
Hjortebjerg, R. & Frystyk, J. Determination of IGFs and their binding proteins. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 771–781 (2013).
Bidlingmaier, M. et al. Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J. Clin. Endocrinol. Metab. 99, 1712–1721 (2014).
Choi, Y. J. et al. Discriminatory performance of insulin-like growth factor 1 and insulin-like growth factor binding protein-3 by correlating values to chronological age, bone age, and pubertal status for diagnosis of isolated growth hormone deficiency. Ann. Pediatr. Endocrinol. Metab. 25, 240–247 (2020).
Inoue-Lima, T. H. et al. IGF-1 assessed by pubertal status has the best positive predictive power for GH deficiency diagnosis in peripubertal children. J. Pediatr. Endocrinol. Metab. 32, 173–179 (2019).
Löfqvist, C. et al. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J. Clin. Endocrinol. Metab. 90, 1420–1427 (2005).
Friedrich, N. et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J. Clin. Endocrinol. Metab. 99, 1675–1686 (2014).
Tillmann, V. et al. Serum insulin-like growth factor-I, IGF binding protein-3 and IGFBP-3 protease activity after cranial irradiation. Horm. Res. 50, 71–77 (1998).
Morrison, K. M. et al. Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly. Eur. J. Endocrinol. 156, 331–339 (2007).
De Rienzo, F. et al. Frequency of genetic defects in combined pituitary hormone deficiency: a systematic review and analysis of a multicentre Italian cohort. Clin. Endocrinol. 83, 849–860 (2015).
Alatzoglou, K. S. et al. Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J. Clin. Endocrinol. Metab. 94, 3191–3199 (2009).
Wagner, J. K., Eblé, A., Hindmarsh, P. C. & Mullis, P. E. Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. Pediatr. Res. 43, 105–110 (1998).
Alatzoglou, K. S. & Dattani, M. T. Genetic causes and treatment of isolated growth hormone deficiency–an update. Nat. Rev. Endocrinol. 6, 562–576 (2010).
Niall, H. D. Revised primary structure for human growth hormone. Nat. New Biol. 230, 90–91 (1971).
Ghizzoni, L. et al. Isolated growth hormone deficiency type IA associated with a 45-kilobase gene deletion within the human growth hormone gene cluster in an Italian family. Pediatr. Res. 36, 654–659 (1994).
Goossens, M., Brauner, R., Czernichow, P., Duquesnoy, P. & Rappaport, R. Isolated growth hormone (GH) deficiency type 1A associated with a double deletion in the human GH gene cluster. J. Clin. Endocrinol. Metab. 62, 712–716 (1986).
Kamijo, T. & Phillips, J. A. Detection of molecular heterogeneity in GH-1 gene deletions by analysis of polymerase chain reaction amplification products. J. Clin. Endocrinol. Metab. 74, 786–789 (1992).
Cogan, J. D. et al. Heterogeneous growth hormone (GH) gene mutations in familial GH deficiency. J. Clin. Endocrinol. Metab. 76, 1224–1228 (1993).
Iughetti, L. et al. Complex disease phenotype revealed by GH deficiency associated with a novel and unusual defect in the GH-1 gene. Clin. Endocrinol. 69, 170–172 (2008).
Hamid, R. et al. A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II. J. Clin. Endocrinol. Metab. 94, 4728–4734 (2009).
Hess, O. et al. Variable phenotypes in familial isolated growth hormone deficiency caused by a G6664A mutation in the GH-1 gene. J. Clin. Endocrinol. Metab. 92, 4387–4393 (2007). A thought-provoking paper detailing the variable penetrance associated with a single mutation in GH1; some patients within the same family with this mutation manifested no phenotype.
Binder, G., Nagel, B. H., Ranke, M. B. & Mullis, P. E. Isolated GH deficiency (IGHD) type II: imaging of the pituitary gland by magnetic resonance reveals characteristic differences in comparison with severe IGHD of unknown origin. Eur. J. Endocrinol. 147, 755–760 (2002).
Salemi, S. et al. Isolated autosomal dominant growth hormone deficiency: stimulating mutant GH-1 gene expression drives GH-1 splice-site selection, cell proliferation, and apoptosis. Endocrinology 148, 45–53 (2007).
Turton, J. P., Buchanan, C. R., Robinson, I. C., Aylwin, S. J. & Dattani, M. T. Evolution of gonadotropin deficiency in a patient with type II autosomal dominant GH deficiency. Eur. J. Endocrinol. 155, 793–799 (2006).
Petkovic, V. et al. GH mutant (R77C) in a pedigree presenting with the delay of growth and pubertal development: structural analysis of the mutant and evaluation of the biological activity. Eur. J. Endocrinol. 157(Suppl 1), 67–74 (2007).
Takahashi, Y. et al. Short stature caused by a mutant growth hormone with an antagonistic effect. Endocr. J. 43(Suppl), 27–32 (1996).
Alba, M. & Salvatori, R. Naturally-occurring missense mutations in the human growth hormone-releasing hormone receptor alter ligand binding. J. Endocrinol. 186, 515–521 (2005).
Godi, M. et al. A recurrent signal peptide mutation in the growth hormone releasing hormone receptor with defective translocation to the cell surface and isolated growth hormone deficiency. J. Clin. Endocrinol. Metab. 94, 3939–3947 (2009).
Demirbilek, H. et al. Familial isolated growth hormone deficiency due to a novel homozygous missense mutation in the growth hormone releasing hormone receptor gene: clinical presentation with hypoglycemia. J. Clin. Endocrinol. Metab. 99, E2730–E2734 (2014).
Gregory, L. C. et al. Partial loss of function of the GHRH receptor leads to mild growth hormone deficiency. J. Clin. Endocrinol. Metab. 101, 3608–3615 (2016).
Zizzari, P. et al. Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor. Endocrinology 146, 3836–3842 (2005).
Pantel, J. et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 116, 760–768 (2006).
Pantel, J. et al. Recessive isolated growth hormone deficiency and mutations in the ghrelin receptor. J. Clin. Endocrinol. Metab. 94, 4334–4341 (2009).
Argente, J. et al. Defective minor spliceosome mRNA processing results in isolated familial growth hormone deficiency. EMBO Mol. Med. 6, 299–306 (2014).
Verberne, E. A., Faries, S., Mannens, M. M. A. M., Postma, A. V. & van Haelst, M. M. Expanding the phenotype of biallelic RNPC3 variants associated with growth hormone deficiency. Am. J. Med. Genet. A 182A, 1952–1956 (2020).
Cogan, J. D. et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J. Clin. Endocrinol. Metab. 83, 3346–3349 (1998).
Deladoëy, J. et al. “Hot spot” in the PROP1 gene responsible for combined pituitary hormone deficiency. J. Clin. Endocrinol. Metab. 84, 1645–1650 (1999).
Ward, R. D. et al. Role of PROP1 in pituitary gland growth. Mol. Endocrinol. 19, 698–710 (2005).
Riepe, F. G. et al. Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. J. Clin. Endocrinol. Metab. 86, 4353–4357 (2001).
Voutetakis, A. et al. Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. J. Clin. Endocrinol. Metab. 89, 2200–2206 (2004).
Radovick, S. et al. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 257, 1115–1118 (1992).
Cohen, R. N. et al. The role of CBP/p300 interactions and Pit-1 dimerization in the pathophysiological mechanism of combined pituitary hormone deficiency. J. Clin. Endocrinol. Metab. 91, 239–247 (2006).
Hoppmann, J. et al. Novel variants in the POU1F1 beta isoform are associated with isolated growth hormone deficiency and combined pituitary hormone deficiency [abstract]. Horm. Res. Paediatr. 89 (Suppl. 1), FC9.1 (2018).
Kale, S. et al. Genetic spectrum and predictors of mutations in four known genes in Asian Indian patients with growth hormone deficiency and orthotopic posterior pituitary: an emphasis on regional genetic diversity. Pituitary 23, 701–715 (2020).
Bashamboo, A., Bignon-Topalovic, J., Rouba, H., McElreavey, K. & Brauner, R. A nonsense mutation in the hedgehog receptor CDON associated with pituitary stalk interruption syndrome. J. Clin. Endocrinol. Metab. 101, 12–15 (2016).
Bashamboo, A., Bignon-Topalovic, J., Moussi, N., McElreavey, K. & Brauner, R. Mutations in the human ROBO1 gene in pituitary stalk interruption syndrome. J. Clin. Endocrinol. Metab. 102, 2401–2406 (2017).
Giri, D. et al. Novel FOXA2 mutation causes hyperinsulinism, hypopituitarism with craniofacial and endoderm-derived organ abnormalities. Hum. Mol. Genet. 26, 4315–4326 (2017).
Karaca, E. et al. Whole-exome sequencing identifies homozygous GPR161 mutation in a family with pituitary stalk interruption syndrome. J. Clin. Endocrinol. Metab. 100, E140–E147 (2015).
Webb, E. A. & Dattani, M. T. Septo-optic dysplasia. Eur. J. Hum. Genet. 18, 393–397 (2010).
Morishima, A. & Aranoff, G. S. Syndrome of septo-optic-pituitary dysplasia: the clinical spectrum. Brain Dev. 8, 233–239 (1986).
Mehta, A. et al. Congenital hypopituitarism: clinical, molecular and neuroradiological correlates. Clin. Endocrinol. 71, 376–382 (2009).
Dattani, M. T. et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat. Genet. 19, 125–133 (1998).
Gaston-Massuet, C. et al. Transcription factor 7-like 1 is involved in hypothalamo-pituitary axis development in mice and humans. Proc. Natl Acad. Sci. USA 113, E548–E557 (2016).
Patel, L., McNally, R. J., Harrison, E., Lloyd, I. C. & Clayton, P. E. Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. J. Pediatr. 148, 85–88 (2006).
Cerbone, M., Güemes, M., Wade, A., Improda, N. & Dattani, M. Endocrine morbidity in midline brain defects: differences between septo-optic dysplasia and related disorders. EClinicalMedicine 19, 100224 (2020).
Kelberman, D. et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J. Clin. Invest. 116, 2442–2455 (2006).
Macchiaroli, A. et al. A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. Gene 534, 282–285 (2014).
Sisodiya, S. M. et al. Role of SOX2 mutations in human hippocampal malformations and epilepsy. Epilepsia 47, 534–542 (2006).
Tajima, T. et al. OTX2 loss of function mutation causes anophthalmia and combined pituitary hormone deficiency with a small anterior and ectopic posterior pituitary. J. Clin. Endocrinol. Metab. 94, 314–319 (2009).
Gregory, L. C. et al. The phenotypic spectrum associated with OTX2 mutations in humans. Eur. J. Endocrinol. 185, 121–135 (2021).
Brachet, C. et al. Truncating RAX mutations: anophthalmia, hypopituitarism, diabetes insipidus, and cleft palate in mice and men. J. Clin. Endocrinol. Metab. 104, 2925–2930 (2019).
Alatzoglou, K. S. et al. SOX3 deletion in mouse and human is associated with persistence of the craniopharyngeal canal. J. Clin. Endocrinol. Metab. 99, E2702–E2708 (2014).
Laumonnier, F. et al. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am. J. Hum. Genet. 71, 1450–1455 (2002).
Woods, K. S. et al. Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am. J. Hum. Genet. 76, 833–849 (2005).
Castinetti, F. et al. A novel dysfunctional LHX4 mutation with high phenotypical variability in patients with hypopituitarism. J. Clin. Endocrinol. Metab. 93, 2790–2799 (2008).
Pfaeffle, R. W. et al. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J. Clin. Endocrinol. Metab. 92, 1909–1919 (2007).
Rajab, A. et al. Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. Hum. Mol. Genet. 17, 2150–2159 (2008).
Gregory, L. C. et al. Novel lethal form of congenital hypopituitarism associated with the first recessive LHX4 mutation. J. Clin. Endocrinol. Metab. 100, 2158–2164 (2015).
Hufnagel, R. B. et al. Neuropathy target esterase impairments cause Oliver-McFarlane and Laurence-Moon syndromes. J. Med. Genet. 52, 85–94 (2015).
McCabe, M. J. et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J. Clin. Endocrinol. Metab. 96, E1709–E1718 (2011).
Roessler, E. et al. Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features. Proc. Natl Acad. Sci. USA 100, 13424–13429 (2003).
Tatsi, C. et al. Pituitary stalk interruption syndrome and isolated pituitary hypoplasia may be caused by mutations in holoprosencephaly-related genes. J. Clin. Endocrinol. Metab. 98, E779–E784 (2013).
Gregory, L. C. & Dattani, M. T. The molecular basis of congenital hypopituitarism and related disorders. J. Clin. Endocrinol. Metab. 105, E2103–E2120 (2020). A recent and up-to-date review of the molecular causes of congenital hypopituitarism.
Correa, F. A. et al. FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies. Endocr. Connect. 4, 100–107 (2015).
Raivio, T. et al. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J. Clin. Endocrinol. Metab. 97, E694–E699 (2012).
Martín, M. G. et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology 145, 138–148 (2013).
Hughes, J. N. et al. Identification of an IGSF1-specific deletion in a five-generation pedigree with X-linked central hypothyroidism without macroorchidism. Clin. Endocrinol. 85, 609–615 (2016).
Di Iorgi, N. et al. The use of neuroimaging for assessing disorders of pituitary development. Clin. Endocrinol. 76, 161–176 (2012).
Vergier, J. et al. DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. Eur. J. Endocrinol. 181, R199–R209 (2019).
Cohen, E. et al. Contribution of LHX4 mutations to pituitary deficits in a cohort of 417 unrelated patients. J. Clin. Endocrinol. Metab. 102, 290–301 (2017).
Deal, C. et al. Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. Horm. Res. Paediatr. 79, 283–292 (2013).
Wang, C. Z. et al. Pituitary stalk interruption syndrome: from clinical findings to pathogenesis. J. Neuroendocrinol. 29, 12451 (2017).
Di Iorgi, N. et al. Classical and non-classical causes of GH deficiency in the paediatric age. Best. Pract. Res. Clin. Endocrinol. Metab. 30, 705–736 (2016).
Maghnie, M., Lindberg, A., Koltowska-Häggström, M. & Ranke, M. B. Magnetic resonance imaging of CNS in 15,043 children with GH deficiency in KIGS (Pfizer International Growth Database). Eur. J. Endocrinol. 168, 211–217 (2013).
Blum, W. F. et al. Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: frequencies, phenotypes and growth outcomes. EBioMedicine 36, 390–400 (2018).
McCormack, S. E. et al. Digenic inheritance of PROKR2 and WDR11 mutations in pituitary stalk interruption syndrome. J. Clin. Endocrinol. Metab. 102, 2501–2507 (2017).
David, O. et al. Pituitary stalk interruption syndrome broadens the clinical spectrum of the TTC26 ciliopathy. Clin. Genet. 98, 303–307 (2020).
Guo, Q. H. et al. Multi-genic pattern found in rare type of hypopituitarism: a whole-exome sequencing study of Han Chinese with pituitary stalk interruption syndrome. J. Cell Mol. Med. 21, 3626–3632 (2017).
Johnson-Tesch, B. A., Gawande, R. S., Zhang, L., MacMillan, M. L. & Nascene, D. R. Fanconi anemia: correlating central nervous system malformations and genetic complementation groups. Pediatr. Radiol. 47, 868–876 (2017).
Zwaveling-Soonawala, N. et al. Clues for polygenic inheritance of pituitary stalk interruption syndrome from exome sequencing in 20 patients. J. Clin. Endocrinol. Metab. 103, 415–428 (2018).
Lodge, E. J. et al. Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development. JCI Insight 5, e134310 (2020).
Argyropoulou, M. I. & Kiortsis, D. N. MRI of the hypothalamic-pituitary axis in children. Pediatr. Radiol. 35, 1045–1055 (2005).
Sari, S. et al. Measures of pituitary gland and stalk: from neonate to adolescence. J. Pediatr. Endocrinol. Metab. 27, 1071–1076 (2014).
Godano, E. et al. Role of MRI T2-DRIVE in the assessment of pituitary stalk abnormalities without gadolinium in pituitary diseases. Eur. J. Endocrinol. 178, 613–622 (2018). This paper provides important evidence for MRI usage without contrast enhancement in the majority of children with GHD.
Severino, M. et al. Midbrain-hindbrain involvement in septo-optic dysplasia. AJNR Am. J. Neuroradiol. 35, 1586–1592 (2014).
Lenz, A. M. & Root, A. W. Empty sella syndrome. Pediatr. Endocrinol. Rev. 9, 710–715 (2012).
Cacciari, E. et al. Empty sella in children and adolescents with possible hypothalamic-pituitary disorders. J. Clin. Endocrinol. Metab. 78, 767–771 (1994).
Scala, M. et al. Familial ROBO1 deletion associated with ectopic posterior pituitary, duplication of the pituitary stalk and anterior pituitary hypoplasia. J. Pediatr. Endocrinol. Metab. 32, 95–99 (2019).
Netchine, I. et al. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat. Genet. 25, 182–186 (2000).
Ybarra, M. et al. A new imaging entity consistent with partial ectopic posterior pituitary gland: report of six cases. Pediatr. Radiol. 50, 107–115 (2020).
Campbell, H. J. & Harris, G. W. The volume of the pituitary and median eminence in stalk-sectioned rabbits. J. Physiol. 136, 333–343 (1957).
Adams, J. H., Daniel, P. M. & Prichard, M. M. Degeneration and regeneration of hypothalamic nerve fibers in the neurohypophysis after pituitary stalk section in the ferret. J. Comp. Neurol. 135, 121–144 (1969).
Surtees, R., Adams, J., Price, D., Clayton, P. & Shalet, S. Association of adverse perinatal events with an empty sella turcica in children with growth hormone deficiency. Horm. Res. 28, 5–12 (1987).
Maghnie, M. et al. Hypothalamic-pituitary dysfunction in growth hormone-deficient patients with pituitary abnormalities. J. Clin. Endocrinol. Metab. 73, 79–83 (1991).
Pinto, G. et al. Pituitary stalk interruption syndrome: a clinical-biological-genetic assessment of its pathogenesis. J. Clin. Endocrinol. Metab. 82, 3450–3454 (1997).
Lubinsky, M. S. Hypothesis: septo-optic dysplasia is a vascular disruption sequence. Am. J. Med. Genet. 69, 235–236 (1997).
Maghnie, M., Larizza, D., Zuliani, I. & Severi, F. Congenital central nervous system abnormalities, idiopathic hypopituitarism and breech delivery: what is the connection? Eur. J. Pediatr. 152, 175 (1993).
Fujita, K. et al. The association of hypopituitarism with small pituitary, invisible pituitary stalk, type 1 Arnold-Chiari malformation, and syringomyelia in seven patients born in breech position: a further proof of birth injury theory on the pathogenesis of “idiopathic hypopituitarism”. Eur. J. Pediatr. 151, 266–270 (1992).
Parks, J. S. Congenital hypopituitarism. Clin. Perinatol. 45, 75–91 (2018).
Murray, P. G. et al. Likelihood of persistent GH deficiency into late adolescence: relationship to the presence of an ectopic or normally sited posterior pituitary gland. Clin. Endocrinol. 71, 215–219 (2009).
Binder, G. et al. Evolving pituitary hormone deficits in primarily isolated GHD: a review and experts’ consensus. Mol. Cell Pediatr. 7, 16 (2020).
Maghnie, M. et al. Dynamic MRI in the congenital agenesis of the neural pituitary stalk syndrome: the role of the vascular pituitary stalk in predicting residual anterior pituitary function. Clin. Endocrinol. 45, 281–290 (1996).
Zenaty, D., Garel, C., Limoni, C., Czernichow, P. & Léger, J. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency. Clin. Endocrinol. 58, 647–652 (2003).
Richmond, E. & Rogol, A. D. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best. Pract. Res. Clin. Endocrinol. Metab. 30, 749–755 (2016).
Lal, R. A. & Hoffman, A. R. Perspectives on long-acting growth hormone therapy in children and adults. Arch. Endocrinol. Metab. 63, 601–607 (2019).
Miller, B. S., Velazquez, E. & Yuen, K. C. J. Long-acting growth hormone preparations – current status and future considerations. J. Clin. Endocrinol. Metab. 105, e2121–e2133 (2020).
Yuen, K. C. J., Miller, B. S. & Biller, B. M. K. The current state of long-acting growth hormone preparations for growth hormone therapy. Curr. Opin. Endocrinol. Diabetes Obes. 25, 267–273 (2018).
Johannsson, G. et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J. Clin. Endocrinol. Metab. 105, E1358–E1376 (2020).
Yang, Y. et al. Efficacy and safety of long-acting growth hormone in children with short stature: a systematic review and meta-analysis. Endocrine 65, 25–34 (2019).
Bakker, B., Frane, J., Anhalt, H., Lippe, B. & Rosenfeld, R. G. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J. Clin. Endocrinol. Metab. 93, 352–357 (2008).
Bang, P. et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm. Res. Paediatr. 75, 335–345 (2011).
Pozzobon, G. et al. Growth hormone therapy in children: predictive factors and short-term and long-term response criteria. Endocrine 66, 614–621 (2019).
Kriström, B. et al. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J. Clin. Endocrinol. Metab. 94, 483–490 (2009).
Ranke, M. B., Lindberg, A. & Board, K. I. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J. Clin. Endocrinol. Metab. 95, 1229–1237 (2010).
Carrascosa, A. et al. Growth hormone secretory status evaluated by growth hormone peak after two pharmacological growth hormone release stimuli did not significantly influence the two-year catch-up growth induced by growth hormone therapy in 318 prepubertal short children with idiopathic growth retardation. Horm. Res. Paediatr. 75, 106–114 (2011).
Ranke, M. B. & Lindberg, A. Predicting growth in response to growth hormone treatment. Growth Horm. IGF Res. 19, 1–11 (2009).
Kaufman, F. R. & Sy, J. P. Regular monitoring of bone age is useful in children treated with growth hormone. Pediatrics 104, 1039–1042 (1999).
Wilson, D. M. Regular monitoring of bone age is not useful in children treated with growth hormone. Pediatrics 104, 1036–1039 (1999).
Martin, D. D., Sato, K., Sato, M., Thodberg, H. H. & Tanaka, T. Validation of a new method for automated determination of bone age in Japanese children. Horm. Res. Paediatr. 73, 398–404 (2010).
Martin, D. D., Schittenhelm, J. & Thodberg, H. H. Validation of adult height prediction based on automated bone age determination in the Paris Longitudinal Study of healthy children. Pediatr. Radiol. 46, 263–269 (2016).
Pinsker, J. E. et al. Automated bone age analysis with lossy image files. Mil. Med. 182, e1769–e1772 (2017).
Crock, P. A. et al. Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. Acta Paediatr. 87, 381–386 (1998).
Darendeliler, F., Karagiannis, G. & Wilton, P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm. Res. 68(Suppl 5), 41–47 (2007).
Mostoufi-Moab, S. et al. Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. Pediatr. Blood Cancer 60, 1766–1771 (2013).
Miller, B. S. & Rosenfeld, R. G. Monitoring rhGH Safety: rhGH registries, SAGhE and future needs. Pediatr. Endocrinol. Rev. 16, 150–161 (2018).
Carel, J. C. et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J. Clin. Endocrinol. Metab. 97, 416–425 (2012).
Sävendahl, L. et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J. Clin. Endocrinol. Metab. 97, E213–E217 (2012). This paper presents a composite analysis of the data collected during the SAGhE study of the long-term safety of GH treatment.
Sävendahl, L. et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol. 8, 683–692 (2020).
Albertsson-Wikland, K. et al. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J. Clin. Endocrinol. Metab. 101, 2149–2159 (2016).
Boguszewski, C. L. & Boguszewski, M. C. D. S. Growth hormone’s links to cancer. Endocr. Rev. 40, 558–574 (2019).
Losa, M. et al. Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence. J. Clin. Endocrinol. Metab. 105, 1573–1580 (2020).
Raman, S. et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy–a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J. Clin. Endocrinol. Metab. 100, 2192–2203 (2015).
Grimberg, A. & Allen, D. B. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr. Opin. Pediatr. 29, 466–471 (2017).
Abs, R. et al. Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur. J. Endocrinol. 168, 297–305 (2013).
Downing, J. et al. Transition in endocrinology: the challenge of maintaining continuity. Clin. Endocrinol. 78, 29–35 (2013).
Yuen, K. C. J. et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr. Pract. 25, 1191–1232 (2019). The most recently updated guidelines for paediatric patients with GHD transitioning to adult care provides a practical tool for more in-depth detail.
Hartman, M. L. et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J. Clin. Endocrinol. Metab. 87, 477–485 (2002).
Einaudi, S. et al. Hypothalamo-hypophysial dysfunction after traumatic brain injury in children and adolescents: a preliminary retrospective and prospective study. J. Pediatr. Endocrinol. Metab. 19, 691–703 (2006).
Gleeson, H. K., Gattamaneni, H. R., Smethurst, L., Brennan, B. M. & Shalet, S. M. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. J. Clin. Endocrinol. Metab. 89, 662–666 (2004).
Alatzoglou, K. S., Webb, E. A., Le Tissier, P. & Dattani, M. T. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr. Rev. 35, 376–432 (2014).
Colao, A. et al. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J. Clin. Endocrinol. Metab. 94, 4414–4422 (2009).
Garcia, J. M. et al. Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocr. Connect. 10, 76–83 (2021).
Kuzma, M. et al. Effect of growth hormone on bone status in growth hormone-deficient adults. Bratisl. Lek. Listy 114, 689–695 (2013).
Davidson, P., Milne, R., Chase, D. & Cooper, C. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin. Endocrinol. 60, 92–98 (2004).
Carroll, P. V. et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J. Clin. Endocrinol. Metab. 89, 3890–3895 (2004).
Yang, H. et al. Body composition and metabolic health of young male adults with childhood-onset multiple pituitary hormone deficiency after cessation of growth hormone treatment. J. Pediatr. Endocrinol. Metab. 31, 533–537 (2018).
Courtillot, C. et al. Monocentric study of 112 consecutive patients with childhood onset GH deficiency around and after transition. Eur. J. Endocrinol. 169, 587–596 (2013).
Elbornsson, M. et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur. J. Endocrinol. 168, 745–753 (2013).
Hwu, C. M. et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J. Clin. Endocrinol. Metab. 82, 3285–3292 (1997).
Hammarstrand, C. et al. Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. Eur. J. Endocrinol. 179, 229–237 (2018).
Attanasio, A. F. et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J. Clin. Endocrinol. Metab. 95, 74–81 (2010).
Luger, A. et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care 35, 57–62 (2012).
Attanasio, A. F. et al. Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J. Clin. Endocrinol. Metab. 96, 2255–2261 (2011).
Lanes, R. et al. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J. Clin. Endocrinol. Metab. 86, 1061–1065 (2001).
Setola, E. et al. Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 57, 1685–1690 (2008).
Tidblad, A., Bottai, M., Kieler, H., Albertsson-Wikland, K. & Sävendahl, L. Association of childhood growth hormone treatment with long-term cardiovascular morbidity. JAMA Pediatr. 175, e205199 (2021).
Grimberg, A. Cardiovascular Disease in former pediatric recipients of growth hormone: another look at growth hormone safety. JAMA Pediatr. 175, e205232 (2021).
Aguiar-Oliveira, M. H. & Salvatori, R. Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome. Rev. Endocr. Metab. Disord. 22, 81–89 (2020). The GHRH signal disruption syndrome in a cohort followed for 26 years has been a valuable model to study the role of GH in body size and function.
Acknowledgements
We are thankful to Prof. Andrea Rossi and Prof. Giovanni Morana for their contributions to the neuroimaging. C.H. acknowledges the support of a generous gift from the Ward Family.
Author information
Authors and Affiliations
Contributions
C.H., H.-W.G., A. I. and G.P. researched data for the article. R.S., M.D. and S.L. contributed substantially to discussion of the content. C.H., H.-W.G., A.I., G.P. and M.M. wrote the article. R.S., M.D., S.L. and M.L. reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
R.S. has served on advisory boards for Novo Nordisk and Ipsen. M.D. has served on advisory boards for Novo Nordisk, Pfizer and Ipsen and has received consulting/lecture fees from Sandoz, Pfizer and Novo Nordisk. M.M. has served on advisory boards for Ascendis, Biomarin, Merck, Novo Nordisk, Pfizer and Merk and has received lecture fees at several meetings. S.L. has received lecture fees and served on advisory board for Merck Serono, Ipsen and Sandoz. The other authors declare no competing interests.
Additional information
Peer review information
Nature Reviews Endocrinology thanks G. Binder, R. Brauner and C. Deal for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
OMIM #615961: https://www.omim.org/entry/615961
PSIS: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=95496
Supplementary information
Glossary
- Ectopic posterior pituitary
-
A disruption of normal embryogenesis of the posterior pituitary resulting in an incomplete downward extension of the diencephalon (infundibulum).
- Holoprosencephaly
-
A syndrome caused by failure of separation of the cerebral hemispheres and ventricles and associated with a wide range of midline facial defects, ranging from cyclopia to midfacial hypoplasia, cleft lip and/or palate and a single incisor.
- T2-DRIVE
-
A T2-weighted driven equilibrium (DRIVE) imaging obtained via turbo fast spin-echo sequences at sub-millimetre thickness, which provide excellent contrast between the cerebrospinal fluid and the adjacent parenchymal structures.
- Slipped capital femoral epiphysis
-
A disorder seen in adolescents in which the growth plate is damaged and the femoral head moves (‘slips’) with respect to the rest of the femur: the head of the femur stays in the cup of the hip joint while the rest of the femur is shifted.
Rights and permissions
About this article
Cite this article
Hage, C., Gan, HW., Ibba, A. et al. Advances in differential diagnosis and management of growth hormone deficiency in children. Nat Rev Endocrinol 17, 608–624 (2021). https://doi.org/10.1038/s41574-021-00539-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-021-00539-5
This article is cited by
-
Screening of GHSR, GHRHR, GH1 genes in isolated growth hormone deficiency disease in Egyptian patients
Egyptian Journal of Medical Human Genetics (2024)
-
Blood pressure response to clonidine in children with short stature is correlated with postural characteristics: a retrospective cross-sectional study
BMC Pediatrics (2024)
-
Aromatase Inhibitors May Increase the Risk of Cardiometabolic Complications in Adolescent Boys
Pediatric Cardiology (2024)
-
The economic burden of pediatric growth hormone deficiency in Italy: a cost of illness study
Journal of Endocrinological Investigation (2024)
-
Growth hormone therapy response in children with short stature
Egyptian Pediatric Association Gazette (2023)